Growth Metrics

KalVista Pharmaceuticals (KALV) Current Deferred Revenue (2014 - 2025)

KalVista Pharmaceuticals recorded quarterly Current Deferred Revenue of $11.4 million in Q3 2025, up 3.75% quarter-over-quarter from $11.0 million in Q2 2025.

KalVista Pharmaceuticals' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $11.4 million for Q3 2025.

  • In Q3 2025, Current Deferred Revenue changed N/A year-over-year to $11.4 million; the TTM figure through Jul 2025 stood at $11.4 million (changed N/A YoY), while the FY2025 annual figure was $11.0 million, changed N/A from the prior year.
  • Current Deferred Revenue came in at $11.4 million for Q3 2025 at KalVista Pharmaceuticals, up from $11.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $11.4 million in Q3 2025 to a low of $11.0 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 KalVista Pharmaceuticals 1.44 Bn 1.25 Bn 56.41 Mn

Historic Data

Download Data 🔒
DateValue
Jul 31, 2025 11.41 Mn
Apr 30, 2025 11.00 Mn
Jan 31, 2020 1.34 Mn
Oct 31, 2019 2.60 Mn
Jul 31, 2019 6.02 Mn
Apr 30, 2019 9.55 Mn
Jan 31, 2019 12.31 Mn
Oct 31, 2018 14.77 Mn
Jul 31, 2018 17.21 Mn
Apr 30, 2018 18.48 Mn
Jan 31, 2018 20.00 Mn
Mar 31, 2016 29,000.00
Dec 31, 2015 29,000.00
Sep 30, 2015 29,000.00
Jun 30, 2015 29,000.00
Dec 31, 2014 29,000.00